亚洲第一大网站,欧美三级网络,日韩av在线导航,深夜国产在线,最新日韩视频,亚洲综合中文字幕在线观看,午夜香蕉视频

產(chǎn)品分類(lèi)導航
2025制藥工業(yè)深圳展
Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism
Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism
Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism
Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism
Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism
Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism
Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism

Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism

更新時(shí)間:2025-06-20

價(jià)格:  元/個(gè)
CAS號: 2023788-19-2
藥典: 中國藥典,企業(yè)標準
級別: injection
立即詢(xún)盤(pán)
收藏
產(chǎn)品詳情
產(chǎn)品關(guān)鍵詞: Dual-Action Agonist,Type 2 Diabetes Treatment,Weight Management,Once-Weekly Dosing,GIP/GLP-1 Receptor Activation
是否為生產(chǎn)商:
產(chǎn)品包裝規格: 5mg/Ampoule 10mg/Ampoule 15mg/Ampoule 20mg/Ampoule 30mg/Ampoule 10Ampoules/Box
主要銷(xiāo)售市場(chǎng): 中國,北美洲,中/南美洲,西歐,東歐,大洋洲,亞洲,中東,非洲
產(chǎn)品描述:






Mechanism of Action(作用機理)

Tirzepatide is a dual-agonist for both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It mimics the actions of these two incretin hormones to enhance glucose homeostasis and appetite regulation:

  1. GIP Receptor Activation: Tirzepatide binds to the GIP receptor, stimulating insulin secretion in a glucose-dependent manner, which helps lower blood glucose levels. It also promotes the clearance of dietary triglycerides and enhances lipid metabolism in adipose tissue.
  2. GLP-1 Receptor Activation: It activates the GLP-1 receptor, leading to additional insulin secretion, suppression of glucagon release, and slowing of gastric emptying. This interaction also reduces appetite and food intake by acting on the central nervous system.
  3. Synergistic Effects: By activating both receptors simultaneously, tirzepatide provides a more potent and comprehensive effect on glucose control and weight management compared to single-agonist therapies.

Applications(應用)

  1. Type 2 Diabetes Management: Tirzepatide is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
  2. Weight Management: It is also indicated for chronic weight management in individuals with obesity or overweight with at least one weight-related comorbidity. Clinical trials have shown significant weight loss benefits.
  3. Other Potential Uses: Ongoing studies are exploring its potential in non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection fraction (HFpEF), obstructive sleep apnea (OSA), and chronic kidney disease (CKD).

Dosage Instructions(用法用量)

  1. Initial Dose: The recommended starting dose is 2.5 mg once weekly.
  2. Titration: The dose can be increased to 5 mg, 7.5 mg, or 10 mg once weekly, depending on the patient's glycemic response and tolerability.
  3. Injection Instructions: Tirzepatide is administered subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to avoid lipodystrophy.
  4. Missed Dose: If a dose is missed, administer as soon as possible within 3 days. If more than 3 days have passed, skip the missed dose and resume the regular schedule.

Storage(保存)

  1. Unopened Pens: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.
  2. Opened Pens: Once opened, pens can be stored at room temperature (not exceeding 30°C/86°F) for up to 8 weeks.
  3. Protection from Light and Heat: Keep the medication away from direct sunlight and high temperatures.


上海浦津林州制藥有限公司
注冊資本
聯(lián)系人
聯(lián)系電話(huà)
查看聯(lián)系方式
快速詢(xún)盤(pán)
詢(xún)盤(pán)主題
請輸入詢(xún)盤(pán)主題
詢(xún)盤(pán)信息
請輸入詢(xún)盤(pán)信息
滑動(dòng)驗證
請完成滑塊驗證
快速發(fā)送詢(xún)盤(pán)
CPHI制藥在線(xiàn)為您找到Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism 價(jià)格、Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism 詳細參數、Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism 相關(guān)產(chǎn)品、Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism 供應商等信息,想了解當前Tirzepatide: A New Frontier in Obesity Therapy with GIP/GLP-1 Mechanism 最新報價(jià),請聯(lián)系上海浦津林州制藥有限公司。
2006-2025 上海博華國際展覽有限公司版權所有(保留一切權利) 滬ICP備05034851號-57
新野县| 溧阳市| 自治县| 大足县| 桦甸市| 兴和县| 连云港市| 东光县| 香港| 正定县| 新龙县| 吐鲁番市| 英山县| 乌海市| 崇仁县| 太仓市| 凤冈县| 德安县| 沛县| 开平市| 会同县| 新昌县| 化德县| 漾濞| 承德县| 务川| 波密县| 北川| 高邮市| 堆龙德庆县| 陕西省| 宁安市| 南郑县| 交城县| 凌海市| 巴楚县| 四川省| 监利县| 洮南市| 施秉县| 墨脱县|